Vivos Therapeutics to Present at the 2026 Moody Capital Solutions Disruptive Growth & Life Sciences Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Vivos Therapeutics (NASDAQ: VVOS) announced that founder and CEO R. Kirk Huntsman will present at the 2026 Moody Capital Solutions Disruptive Growth & Life Sciences Conference at The Westin New York Grand Central in New York City on September 9, 2026, at 8:45 a.m. Eastern Time. Management will also hold a Q&A session and be available for one-on-one meetings with institutional investors during the conference.
Details
News Market Reaction – VVOS
On Sep 1, the day this news came out, VVOS closed 13.98% below the previous close. Argus tracked a trough of -16.4% from its starting point during tracking. Our momentum scanner recorded 41 alerts for this stock that day. Relative volume reached 2478.4x the daily average during tracking.
Data tracked by StockTitan Argus for the Sep 1 session.
Key Figures
- Announcement Date
- September 1, 2026
- Press release date
- Conference Dates
- September 9 and 10, 2026
- 2026 Moody Capital Solutions conference
- Presentation Date
- September 9, 2026
- Scheduled company presentation
- Presentation Time
- 8:45 a.m. Eastern Time
- Scheduled presentation time
Historical Context
-
Signed agreements to launch a regional sleep testing and treatment center
-
Reported 212% growth in average weekly new patient referrals
-
Announced Henderson facility expected to exceed $10 million annual capacity
-
Reported higher revenue alongside larger losses and limited cash
-
Scheduled second-quarter results and an investor conference call
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
obstructive sleep apnea medical
osa medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Littleton, Colorado--(Newsfile Corp. - September 1, 2026) - Vivos Therapeutics, Inc. (NASDAQ: VVOS) ("Vivos" or the "Company"), a leading medical technology and healthcare services company focused on the diagnosis and treatment of obstructive sleep apnea (OSA) and related breathing and sleep disorders, today announced that Founder and Chief Executive Officer R. Kirk Huntsman will present at the 2026 Moody Capital Solutions Disruptive Growth & Life Sciences Conference, taking place September 9 and 10, 2026, at The Westin New York Grand Central in New York City.
Mr. Huntsman is scheduled to present on Wednesday, September 9, 2026, at 8:45 a.m. Eastern Time, followed by a question-and-answer session. Company management will also be available for one-on-one meetings with institutional investors throughout the conference.
"Given the significant and positive trends that our business has been taking over the past few months, this is a perfect time to get our message out to the financial markets," said Mr. Huntsman. "We look forward to visiting with investors and telling our amazing story."
Investors interested in scheduling a meeting with Vivos management should contact their Moody Capital Solutions representative or the Company at the contact listed below.
Investor Relations Contact:
Jennifer Hauser
Executive Assistant to the CEO
jhauser@vivoslife.com
720-927-3125
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/312338
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.